TAZTIA XT SUMMARY
Diltiazem hydrochloride is a calcium ion cellular influx inhibitor (slow channel blocker).
Diltiazem Hydrochloride Extended-Release Capsules USP (Once-a-Day Dosage) are indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive medications.
Chronic Stable Angina
Diltiazem Hydrochloride Extended-Release Capsules USP (Once-a-Day Dosage) are indicated for chronic stable angina.
Published Studies Related to Taztia XT (Diltiazem)
Topical diltiazem cream versus botulinum toxin a for the treatment of chronic
anal fissure: a double-blind randomized clinical trial. 
the purpose of this study... CONCLUSIONS: BTA yields higher healing rates in the short term, though after 3
Effects of diltiazem on pharmacokinetics of tacrolimus in relation to CYP3A5 genotype status in renal recipients: from retrospective to prospective. [2011.08]
The impact of CYP3A5*3, a CYP3A5 nonexpresser genotype, on inhibitory effects of diltiazem on tacrolimus metabolism has not been assessed. In retrospective study, when coadministered with diltiazem, mean increments in dose-adjusted C(0D7), C(max) and AUC(0-12 h) for tacrolimus were larger in CYP3A5 expressers than in CYP3A5 nonexpressers (48.7 vs 3.7%, 31.7 vs 17.2% and 38.2 vs 18.5%, respectively).
A randomized, prospective, double-blind, placebo-controlled trial of the effect of topical diltiazem on posthaemorrhoidectomy pain. [2011.03]
CONCLUSION: Perianal application of DTZ cream after haemorrhoidectomy significantly reduces postoperative pain and is perceived as beneficial, with no increase in associated morbidity. (c) 2011 The Authors. Colorectal Disease (c) 2011 The Association of Coloproctology of Great Britain and Ireland.
[A comparative study on the efficacy and safety of intravenous esmolol, amiodarone and diltiazem for controlling rapid ventricular rate of patients with atrial fibrillation during anesthesia period]. [2010.11]
OBJECTIVE: To evaluate the efficacy and safety of intravenous esmolol, amiodarone and diltiazem for controlling rapid ventricular rate in patients with atrial fibrillation (AF) during anesthesia period... CONCLUSIONS: Intravenous esmolol, amiodarone and diltiazem are all equally effective and safe on controlling rapid ventricular rate in patients with atrial fibrillation during the anesthesia period. Esmolol use is associated with the shortest mean reacting time and amiodarone use is associated with the lowest total side effect rate in this patient cohort.
Comparison of the effects of long-acting nifedipine CR and diltiazem R in patients with vasospastic angina: Aomori coronary spastic angina study. [2010.11]
CONCLUSION: Once-daily administration of nifedipine CR was as effective as twice-daily diltiazem R in the prevention of VSA attacks. Copyright (c) 2010 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
Clinical Trials Related to Taztia XT (Diltiazem)
Study Investigating the Pharmacokinetic Interaction Between INX-08189 and Verapamil HCL ER in Healthy Volunteers [Recruiting]
The purpose of this study is to evaluate the potential for a pharmacokinetic (PK) drug-drug
interaction between INX-08189 and extended release verapamil hydrochloride (verapamil HCL
Verapamil as Therapy for Children and Young Adults With Dravet Syndrome [Recruiting]
This study will assess how well the drug verapamil can improve control of seizures and
dysautonomia symptoms in children and young adults diagnosed with Dravet syndrome. The
safety of verapamil when given with all concomitant medications will also be assessed.
Verapamil vs. Sertraline for Vestibular Migraine & Chronic Subjective Dizziness [Recruiting]
Chronic dizziness and recurrent vertigo are frequent complaints in primary and specialty
medical care settings. Two common causes of these symptoms are vestibular migraine (VM) and
chronic subjective dizziness (CSD), which may be seen in up to 25% of patients examined in
tertiary neurotology centers. However, VM and CSD are relatively new diagnoses that have
not yet been validated. Furthermore, recent research found that they co-exist 30% of the
time with overlap in several features. From a clinical standpoint, this makes it difficult
to diagnose and treat them well. From a research standpoint, it confounds subject selection
for mechanistic investigations.
The primary goal of this study to dissect VM and CSD in order to identify the key features
and clarify the diagnostic criteria of each condition. Fifty patients diagnosed with
coexisting VM-CSD will be treated with either verapamil or sertraline. Based on clinical
and research experience to date, verapamil is thought to have greater effect on
migraine-related symptoms, whereas sertraline is thought to have greater effect on
CSD-related symptoms. It is hypothesized that a differential treatment response to these
two pharmacologic probes will help to tease apart the unique clinical features of VM and CSD
and identify risk factors that are shared or separate between the two conditions. The
different mechanisms of action of the two study medications may also shed light on the
physiologic underpinnings of VM and CSD.
This project will be a 14-week, prospective, randomized, double-blind, parallel group,
pharmacologic dissection trial. A 12-week treatment period will follow 2 weeks of baseline
observation. Patients will chart daily headache and vestibular symptoms. VM and CSD
symptoms and potential confounds such as anxiety and depression will be measured at two week
intervals. Data will be analyzed for differential and shared treatment effects that align
with or oppose current concepts of VM and CSD.
Safety, Tolerability, and Efficacy of IA Verapamil in the Treatment of Joint Pain in Subjects With Osteoarthritis of the Knee [Recruiting]
This is a randomized, double-blind, placebo-controlled, multi-center study to evaluate the
safety, tolerability, and efficacy of Intra-Articular (IA) verapamil in the treatment of
joint pain in patients with knee osteoarthritis (OA). Subjects will discontinue all
analgesic medications for the entire duration of the study, except for acetaminophen (taken
on an as needed basis at no more than 2 g/day). At visit 2, subjects who meet all entry
criteria will be randomized to receive a single injection of IA verapamil or IA placebo at a
ratio of 1: 1. Treatments will be given with fluoroscopy or ultrasound to confirm needle
placement. Subjects will be monitored for blood pressure and heart rate (sitting and
standing) for at least 1 hour post-injection. Subjects will be evaluated at weeks 1, 2, 3,
4, 6, 8, and 12 after treatment.
Evaluation of the Drug-drug Interaction Between FosD and Verapamil When Taken Together in Healthy Volunteers [Not yet recruiting]
This Study evaluates the possible drug interaction between FosD and verapamil when taken
Page last updated: 2013-02-10